Oramed Pharmaceuticals (ORMP) Q2 2026 earnings summary

Executive summary

• Transitioned to a strategic healthcare operating model, focusing on value creation through active ownership and operational leadership in portfolio companies.

• Closed the Lifeward transaction, transferring the oral insulin platform and securing significant equity and financial instruments in Lifeward.

• Expanded investment portfolio with new real estate and private equity fund commitments, and continued active management of marketable securities.

Financial highlights

• Net income for the six months ended June 30, 2026 was $116.5M, up from $5.6M in the prior year period.

• Financial income, net, surged to $148.6M from $12.8M year-over-year, mainly due to revaluation gains on Alpha Tau and other investments.

• Operating loss decreased 8% to $6.4M for the six months, driven by lower R&D expenses.

• Cash and cash equivalents declined to $15.2M as of June 30, 2026, from $45.9M at year-end 2025.

• Working capital surplus was $42.7M as of June 30, 2026.

Outlook and guidance

• Current cash resources and commitments are expected to support planned activities for at least the next 12 months.

• No significant R&D expenses anticipated as clinical development is now managed by OraTech.

• Actively evaluating strategic alternatives, including new investments and business acquisitions.